Drug intelligence / Profile preview

JMEY-002

Development stage: Preclinical
Lead developer: Jianming Pharmaceutical Group

Overview

JMEY-002 is an investigational drug candidate currently in the preclinical stage of development by Jianming Pharmaceutical Group (Wuhan Jianming Pharmaceutical). It is being developed for the treatment of allergic conditions. Detailed information regarding its molecular target, chemical structure, or specific modality has not been publicly disclosed in the company's pipeline documentation. The program is currently categorized within the CMC and preclinical development phase.

Beyond the preview

Go deeper on JMEY-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMEY-002.

Explore the full profile